Pharma
Commented by André Will-Laudien on August 23rd, 2023 | 07:00 CEST
Climate change or just a heat wave? - BioNTech, Cardiol Therapeutics, and Redcare Pharmacy deliver!
Whether this consistently warm summer already documents a pronounced climate change is questionable. The older ones among us remember that there were already very hot summers before and that even in the last 30 years, there was rarely snow at Christmas. However, human life is simply too short for significant conclusions. Therefore, long-term weather records have to be consulted. There will probably be a slight increase in average temperatures, but we will get little information about when the next ice age will hit us. For many politicians, the current weather trends fit perfectly into the chain of arguments in favor of radical legislative proposals. Perhaps, however, the caprices of the weather are only the offshoots of the approaching El Nino. The stock market also follows changing trends; after the flood, an ebb could now be imminent. Selection remains key!
Read
Commented by Armin Schulz on August 16th, 2023 | 05:40 CEST
BioNTech, Defence Therapeutics, Bayer - Who will have trend-setting news first?
Pharmaceutical and biotech stocks are among the most volatile sectors in the financial markets. Single news stories about new developments or product announcements can not only cause short-term price swings but also have long-term implications, increasing both risk and opportunity for investors. If a breakthrough drug is developed, old preparations can become obsolete - this is good for the innovative company but detrimental to established market participants. As an investor, it is advisable to select specific companies and anticipate directional news through some research.
Read
Commented by Stefan Feulner on August 2nd, 2023 | 09:15 CEST
Well positioned for the future - BioNTech, Defence Therapeutics, Sanofi
There is currently a lot of movement in the capital-intensive biotech sector. After second-tier companies, in particular, were hit hard by the effects of tighter monetary policy last year and at times traded below their cash levels, many are now considered hot takeover candidates thanks to their innovative technologies. The well-heeled pharma giants must act to avoid missing out on future blockbusters.
Read
Commented by Stefan Feulner on August 1st, 2023 | 09:00 CEST
Biogen, Cardiol Therapeutics, Evotec - The acquisition wave is rolling
The biotechnology industry has seen a significant increase in acquisitions and mergers in recent months. Large pharmaceutical companies are looking to expand their portfolios to provide innovative solutions for unmet medical needs. At the same time, despite an increase in value in recent months, acquisition targets are still attractively valued due to the sell-off over the past year.
Read
Commented by Armin Schulz on July 31st, 2023 | 09:20 CEST
Bayer, Defense Metals, Alibaba - Stocks with doubling potential
Discovering stocks with high growth potential during difficult market periods is a challenging task. While there is no guarantee that a stock will double in value, certain factors can help identify companies with promising growth prospects. One effective approach is to focus on industries that offer growth opportunities even in adverse market conditions. Otherwise, examining fundamentals and ensuring the story fits the current spirit of the times is advisable. We have selected three possible doubling candidates.
Read
Commented by Stefan Feulner on July 25th, 2023 | 09:45 CEST
Sartorius, BioNxt Solutions, CENIT AG - Attack from the Second Row
While some of the big caps have already reached new highs in the current stock market year 2023, many undiscovered second-tier stocks are still a long way off. At the same time, companies, most of which rely on disruptive technologies, possess powerful potential. If the ambitious goals are achieved, investors can expect above-average returns.
Read
Commented by Armin Schulz on July 19th, 2023 | 07:45 CEST
Pfizer, Cardiol Therapeutics, Bayer - Pharma facing turnaround despite drug shortages?
In mid-June, there was a shortage of 470 prescription drugs in Germany, according to the Federal Institute for Drugs and Medical Devices. However, not only Germany is suffering from a shortage, but all of Europe. Once again, the dependence on China is the underlying cause. The EU is seeking countermeasures, but this will be challenging because capped prices, bureaucracy and rising energy costs make a location like Germany seem less attractive. At the same time, demographic change means that society needs the pharmaceutical industry more and more urgently. Therefore, we look at three companies that aim to heal sick people.
Read
Commented by Nico Popp on July 11th, 2023 | 07:30 CEST
Returns thanks to e-prescription and co.: Redcare Pharmacy, BB Biotech, Cardiol Therapeutics
There are attractive returns to be had in the healthcare sector. Innovative approaches around data and biotechnology are particularly promising, according to Daniel Matviyenko, Portfolio Manager of Healthcare Strategies at Jennison Associates. But what does this innovation look like in concrete terms? And how can investors invest? We highlight the healthcare industry using three companies as examples, with a special focus on opportunities in select individual stocks.
Read
Commented by André Will-Laudien on June 30th, 2023 | 07:30 CEST
Doublers are possible! Bayer, Defence Therapeutics, BioNTech, Valneva - It is hard to believe!
In 2022, a total of 19.5 million people received the shocking diagnosis of "cancer". Current trends, unfortunately, suggest that this number will continue to rise in the coming years. However, thanks to growing research successes, there is hope that biotechnology will significantly increase the chances of survival for those affected. It is a matter of developing suitable active substances and launching modern therapies. mRNA technology has recently made a name for itself in cancer prevention. Innovative biotech companies are back on the radar of risk-conscious investors. We are on the lookout for doubling potential.
Read
Commented by Fabian Lorenz on June 21st, 2023 | 08:40 CEST
Biotech comeback! Profit with BioNTech, Morphosys and BioNxt Solutions
Biotech shares have not been among the favourites on the stock market in recent months. After the Corona hype, they were overshadowed by BigTech and especially AI. Sartorius, BioNTech and Co. have corrected strongly. But in the meantime, there are strong signs of a comeback - led by Morphosys. The share of the German biotech veteran has doubled since the beginning of April. MediGene and Evotec have also recorded price jumps. Are BioNTech and BioNxt Solutions next? Morphosys also continues to be praised by analysts. But Goldman Sachs wants to end the party.
Read